An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects Against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model
Authors:
- 28 November 2013
- journal article
- Published by Taylor & Francis in Future Virology
- Vol. 8 (12) , 1151-1160
Abstract
Aim: Congenital human CMV (HCMV) infection can lead to long-term neurodevelopmental sequelae, including mental retardation and sensorineural hearing loss. Preconception vaccine strategies relevant to the prevention of HCMV-mediated injury to the newborn can be studied in the Guinea pig CMV (GPCMV) model. The objectives of this study were: to assess in Guinea pigs the protective efficacy against congenital infection and disease of a recombinant live, attenuated vaccine with a targeted deletion of the GPCMV homolog of the HCMV pUL83 tegument protein, GP83; and to compare the extent of placental infection in vaccine and control groups using an in situ hybridization assay. Materials & methods: Outbred Hartley Guinea pigs were vaccinated prior to pregnancy with a two-dose series of 5 × 104 PFU of vAM409, a GP83 deletion virus. Deletion of the GP83 gene resulted in an attenuated virus, and vAM409-vaccinated animals did not demonstrate evidence of DNAemia following vaccination, although ELISA antibody responses ...Keywords
Funding Information
- National Institutes of Health (R01HD044864, R01HD038416)
This publication has 38 references indexed in Scilit:
- Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge modelVaccine, 2014
- An Attenuated Cytomegalovirus Vaccine with a Deletion of a Viral Chemokine Gene Is Protective against Congenital CMV Transmission in a Guinea Pig ModelJournal of Immunology Research, 2013
- Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected WomenThe Journal of Infectious Diseases, 2011
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- Update on the current status of cytomegalovirus vaccinesExpert Review of Vaccines, 2010
- A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infectionVaccine, 2009
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Neuropathogenesis of Congenital Cytomegalovirus Infection: Disease Mechanisms and Prospects for InterventionClinical Microbiology Reviews, 2009
- Targeted Deletion of Regions Rich in Immune-Evasive Genes from the Cytomegalovirus Genome as a Novel Vaccine StrategyJournal of Virology, 2007
- Preconception Vaccination with a Glycoprotein B (gB) DNA Vaccine Protects against Cytomegalovirus (CMV) Transmission in the Guinea Pig Model of Congenital CMV InfectionThe Journal of Infectious Diseases, 2003